Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258865 | 0.84 | KIF11 (0.60) | KMT2ATRPV1ALDH1A1TP53TSHR | |
| SCHEMBL8332645 | 0.84 | TRPV1 (0.48) | TRPV1ALDH1A1RXFP1UBE2MDCUN1D1 | |
| SCHEMBL5525900 | 0.80 | KIF11 (0.63) | KMT2ATRPV1ALDH1A1TP53TYR | |
| SCHEMBL651726 | 0.78 | MAPT (0.64) | KMT2ACYP1A2ALDH1A1TP53TYR | |
| SCHEMBL24265413 | 0.78 | TRPV1 (0.43) | CYP1A2TRPV1ALDH1A1TSHRRXFP1 | |
| SCHEMBL19364344 | 0.78 | TRPV1 (0.46) | TRPV1ALDH1A1TSHRRXFP1UBE2M | |
| SCHEMBL11738389 | 0.77 | L3MBTL1 (0.59) | CYP1A2TRPV1ALDH1A1HSD17B10RXFP1 | |
| SCHEMBL4047674 | 0.76 | KMT2A (0.76) | KMT2ACYP1A2ALDH1A1TP53TYR | |
| SCHEMBL230618 | 0.75 | IDO1 (0.71) | KMT2ACYP1A2ALDH1A1IDO1 | |
| SCHEMBL8349598 | 0.74 | RXFP1 (0.44) | TRPV1ALDH1A1TSHRRXFP1UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | KMT2A 792/4885CYP1A2 407/4885TRPV1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.